Saturday 17 October 2026 Export NVOS’s income statement to Excel — free account

Novo Integrated Sciences, Inc.

Novo Integrated Sciences, Inc.’s revenue for fiscal 2024 (year ended August 2024) was $13.3 million, up 5.75% from fiscal 2023. Revenue growth for five consecutive years.

0.00 0.00 NaN

Follow NVOS

Alert me

Market cap: $730.0K
P/E: 0.0×
Fwd P/E: −10.1×
Dividend yield: —
F-score: 3/9
Altman Z: −4.39
Beneish M: −4.29
Dividend safety: n/a

Overview Business Profile Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 2.78%

Capital & Financial Ratios $m

Market Cap 0.73

Revenue 13.29

Net Income (16.13)

Free Cash Flow (5.12)

Net Debt 0.23

Current Ratio 0.37

Debt/Equity 0.07

P/E ratio 0.00

Fwd P/E (10.10)

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth —

Next Y EPS Growth —

Next Y revenue growth 18.44%

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

EV/Sales against its own 10 years 13.71%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2021	2022	2023	2024
Cash	8	2	0	1
Receivables	2	2	3	3
Inventory	0	1	1	1
Other	—	—	—	—
	11	6	4	5

	2021	2022	2023	2024
Payables	1	2	4	3
ST’ Debt	4	10	1	1
Other	0	1	1	5
	8	14	8	15

Compound Annual Growth %

	10y	5y	3y
Sales	—	7.13%	12.63%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	99.27%	(10.57%)	(30.64%)

Revenue $m

	Nov	Feb	May	Aug	Year
’26	—	—	—	—	—
’24	4	3	3	3	13
’23	3	3	3	3	13
’22	3	3	14	(8)	12
’21	2	2	2	3	9
’20	3	2	1	2	8
’19	2	2	2	2	9

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Nov	Feb	May	Aug	Year
’26	—	—	—	—	—
’24	(2)	(2)	(1)	(1)	(5)
’23	0	(1)	(1)	0	(2)
’22	(1)	(2)	(4)	1	(6)
’21	0	0	0	(1)	(1)
’20	0	0	0	0	0
’19	0	0	0	0	(1)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Nov	Feb	May	Aug	Year
’26	—	—	—	—	—
’24	(2)	(2)	(1)	(1)	(5)
’23	0	(1)	(1)	0	(2)
’22	(1)	(2)	(4)	1	(6)
’21	0	0	0	(1)	(1)
’20	0	0	0	0	0
’19	0	0	0	0	(1)

Fiscal quarters ending in the months shown.

EPS $

	Nov	Feb	May	Aug	Year
’26	—	—	—	—	—
’24	(0.28)	(0.16)	(0.74)	0.31	(0.89)
’23	(1.20)	(0.60)	(0.10)	0.55	(1.30)
’22	(0.70)	(1.70)	(1.30)	(7.60)	(11.30)
’21	(0.33)	(0.60)	(0.20)	(0.80)	(1.80)
’20	0.00	(0.22)	(0.04)	(1.87)	(2.14)
’19	(0.01)	(0.01)	0.00	0.00	(0.02)

Fiscal quarters ending in the months shown.

Group	Line	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025e
Price, $
Price, $	Low	—	3.00	20.21	11.36	11.00	9.70	12.00	1.95	0.66	0.03	Analyst estimates 2025–2027 Powerpack
	High	—	65.00	100.00	299.00	235.00	80.00	149.80	33.20	5.38	1.41
People
People	Employees	—	0	61	86	70	110	172	206	230	264
	Revenue/emp, $m	—	0.00	0.13	0.10	0.13	0.07	0.05	0.06	0.05	0.05
Income, $m
Income, $m	Revenue	—	7	8	9	9	8	9	12	13	13
	Gross margin, %	—	34.93	37.39	38.49	37.35	38.91	41.08	40.89	39.39	43.19
	EBT	—	0	(1)	(2)	0	(5)	(4)	(33)	(13)	(16)
	EBT margin, %	—	0.00	(7.96)	(23.80)	(4.28)	(62.64)	(48.05)	(281.72)	(105.55)	(121.32)
	Net income	—	0	(1)	(2)	0	(5)	(4)	(33)	(13)	(16)
	Depreciation	—	0	0	0	0	1	2	9	7	9
Per share, $
Per share, $	Revenue	—	0.00	0.45	0.43	0.43	3.41	3.76	4.03	1.24	0.74
	Earnings	—	(0.07)	(0.04)	(0.10)	(0.02)	(2.14)	(1.80)	(11.30)	(1.30)	(0.89)
	Cash flow	—	(0.05)	(0.05)	(0.04)	(0.04)	(0.19)	(0.41)	(2.02)	(0.22)	(0.28)
	Capex	—	0.00	0.00	(0.01)	0.00	(0.01)	(0.10)	(0.07)	0.00	0.00
	Free cash flow	—	(0.05)	(0.05)	(0.05)	(0.04)	(0.20)	(0.52)	(2.08)	(0.23)	(0.28)
	Book value	—	0.02	(0.24)	0.01	1.18	12.84	17.68	7.57	2.41	0.81
	Shares, m	—	2	18	21	22	2	2	3	10	18
Valuation, ×
Valuation, ×	P/E	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	0.00	62.48	233.37	85.34	11.72	4.85	4.13	1.13	0.39
	P/B	—	0.00	0.00	12,012.09	31.48	3.12	1.03	2.20	0.58	0.36
	EV/Sales	—	0.00	63.53	233.97	85.38	11.59	5.10	4.49	1.20	0.41
	EV/FCF	—	1,104.35	(495.36)	(1,869.53)	(865.04)	(198.74)	(36.79)	(8.68)	(6.58)	(1.06)
Cash, $m
Cash, $m	Operating cash flow	—	0	(1)	(1)	(1)	0	(1)	(6)	(2)	(5)
	Capex	—	0	0	0	0	0	0	0	0	0
	Free cash flow	—	0	(1)	(1)	(1)	0	(1)	(6)	(2)	(5)
Balance, $m
Balance, $m	Working capital	—	0	(1)	(1)	1	2	3	(8)	(4)	(9)
	Total debt	—	5	6	3	3	1	11	11	1	1
	Net debt	—	0	4	2	1	(1)	2	9	1	0
	Shareholders’ equity	—	0	(4)	0	26	30	44	22	24	15
Returns, %
Returns, %	ROA	—	(11.14)	(26.45)	(41.10)	(2.12)	(14.53)	(9.17)	(63.89)	(34.58)	(47.76)
	ROIC	—	0.00	0.00	(44.19)	(1.88)	(9.33)	(5.93)	(50.20)	(21.09)	(42.44)
	ROE	—	4.69	34.85	102.44	(3.05)	(17.84)	(12.16)	(99.77)	(56.78)	(82.67)

Negative figures in brackets.

All 10 years →

Fiscal years to Aug 2024 · latest quarter Aug 2024

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CANOQ Cano Health, Inc.	$6.6M	— (loss-making)	—	−21.05% (below 0%: shrinking)	n/m	−43.68% (below 0%: shrinking)	100.00%	(16.23%)	Compare
MODVQ ModivCare Inc.	$6.2M	— (loss-making)	— (loss-making)	−3.18% (below 0%: shrinking)	n/m	−3,767.70% (below 0%: shrinking)	14.06%	(1.78%)	Compare
BMGL Basel Medical Group Ltd	$6.2M	—	—	—	—	—	—	—	Compare
RHEP Adcare Health Systems Inc	$5.2M	0.6×	— (loss-making)	+143.03% (above 0%: growing)	n/m	+224.45% (above 0%: growing)	31.50%	(0.88%)	Compare
NIVF NewGenIvf Group Limited	$2.3M	—	—	—	—	—	—	—	Compare
SYRA Syra Health Corp.	$1.1M	84.0×	—	+23.03% (above 0%: growing)	n/m	−892.68% (below 0%: shrinking)	44.53%	10.51%	Compare
NVOS Novo Integrated Sciences, Inc.	$730.0K	— (loss-making)	— (loss-making)	−6.74% (below 0%: shrinking)	−43.27% (below 0%: shrinking)	−111.85% (below 0%: shrinking)	51.21%	(87.60%)
IONM Assure Holdings Corp.	$330.0K	— (loss-making)	— (loss-making)	−98.51% (below 0%: shrinking)	n/m	+95.63% (above 0%: growing)	(22,800.00%)	(138,800.00%)	Compare
BACK IMAC Holdings, Inc.	$150.0K	— (loss-making)	— (loss-making)	+34.18% (above 0%: growing)	n/m	−30.92% (below 0%: shrinking)	(484.43%)	(12,271.70%)	Compare
Median of peers	$3.8M	—	—	+9.93%	—	−37.30%	22.78%	(9.00%)

All 55 Medical Care Facilities stocks →

Novo Integrated Sciences, Inc. (NVOS) key facts

Strength: Novo Integrated Sciences, Inc.’s revenue for fiscal 2024 (year ended August 2024) was $13.3 million, up 5.75% from fiscal 2023.
Novo Integrated Sciences, Inc. (NVOS) is a Medical Care Facilities company in the Healthcare sector.
Return on equity was −82.7% and debt-to-equity 0.07.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −4.39 (distress zone) for fiscal 2024.

Source: company filings (standardised) and stockrow calculations.